Financial updates
Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow
Pharming Group N.V. presents its preliminary (unaudited) financial report for the three months ended September 30, 2025.
- Total third quarter 2025 revenues increased by 30% to US$97.3 million, compared to third quarter 2024
- RUCONEST® third quarter revenue increased by 29% to US$82.2 million, compared to third quarter 2024, reflecting sustained growth in patients and prescribers
- Joenja® (leniolisib) third quarter revenue increased by 35% to US$15.1 million, compared to third quarter 2024, reflecting strong growth in patients on therapy
- FDA granted priority review of sNDA for leniolisib for children aged 4 to 11 years with APDS with decision expected by January 2026
- Third quarter operating profit increased by 285% to US$15.8 million, compared to US$4.1 million in the third quarter 2024
- Generated US$32.0 million in cash flow from operations during the quarter and US$44.0 million year to date
- 2025 total revenue guidance raised to US$365 - US$375 million, up from prior US$335 - US$350 million
- Leverne Marsh appointed Chief Commercial Officer, effective January 1, 2026; Stephen Toor to step down as CCO at year-end and remain an advisor to the company
- Pharming to host a conference call today at 13:30 CET (7:30 am ET) (view webcast)